Xcout Intel
VILLYA LLC
Villya LLC is a pharmaceutical company that develops second-generation medications and proprietary delivery technologies aimed at improving the function, solubility, and administration of traditional drugs and peptides. Using patented technology, the company focuses on creating water-soluble formulations and alternative delivery methods, including oral options for treatments such as Praziquantel, Sildenafil, Semaglutide, and insulin.
Subscribe to see VILLYA LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
VILLYA LLC at a glance
VILLYA LLC is a pharmaceuticals company headquartered in United States. Its most recent funding round, Series A, raised $71M in June 2024. Xcout tracks 2 named people at VILLYA LLC, including Sreeshailam Aare (CSO (CHIEF SCIENTIFIC OFFICER)).
VILLYA LLC leadership
- Sreeshailam AareCSO (CHIEF SCIENTIFIC OFFICER)
- William MillerCEO (CHIEF EXECUTIVE OFFICER)
VILLYA LLC funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $71M | 14 named | |
| SEC Form D filing | $250,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
VILLYA LLC competitors
A few of VILLYA LLC's closest competitors — see the full list of competitors and alternatives →
Pila Pharma AB is a clinical-stage biotechnology company that develops oral TRPV1 antagonists as potential treatments for obesity and diabetes. The company serves patients suffering from these metabolic conditions by advancing innovative, non-injectable drug candidates through preclinical and clinical research.
Vesalius Longevity Labs operates a B2Doctor platform that provides peptide therapeutics and related products exclusively to licensed healthcare providers and clinical networks. The company manufactures and distributes peptides across multiple delivery formats—including subcutaneous, transdermal, intranasal, oral, and topical—utilizing cGMP-aligned manufacturing and third-party verification.
Smartech Topical, Inc. is a specialty pharmaceutical company that develops patented delivery technology for topical pharmaceutical healthcare solutions. The company focuses on advancing pharmaceutical deliverables across key healthcare categories to improve consumer health and wellbeing.
Wegovy provides semaglutide injections and pills for weight management and weight loss in adults with obesity or overweight. The company offers product options, dosing information, guidance, and savings resources for patients.
Vigonvita Life Sciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. Its products include LV232, a first-in-class dual-target 5-HTT/5-HT modulators, which is in Phase II of clinical trial for the treatment of depressive disorder; and TPN171, a type-5 phosphodiesterase inhibitor completed Phase III clinical trial for the treatment of erectile dysfunction. The company also develops VV116, a RNA-dependent RNA polymerase inhibitor completed a Phase II clinical trial for the treatment of respiratory syncytial virus infection, as well as COVID-19 infections; TPN102, a novel antiepileptic drug, which is in Phase I clinical trial for the treatment of epilepsy; VV119, a multi-target serotonin-dopamine activity modulator, which is in Phase I clinical trial for the treatment of psychiatric disorders and schizophrenia; VV261, a novel nucleoside prodrug, which is in Phase I clinical trial for chikungunya, coronaviruses, influenza, and arena virus. In addition, it develops VV913, a novel investigational drug candidate for premature ejaculation; VV147 for the treatment of major depressive disorder; and VV207 for the treatment of adenovirus infection. The company was incorporated in 2013 and is headquartered in Suzhou, China.
J2 Bio-Pharma, LLC is a specialty pharmaceutical company that reformulates neurology medications to address unmet medical needs. The company partners with pharmacies, patients, and businesses in the healthcare sector to develop and commercialize therapeutic products.
Get VILLYA LLC's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on VILLYA LLC in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access